MedLab Clinical (ASX: MDC) has released and update on their medicinal cannabis product – Nanabis, which contains a 1:1 ratio of CBD and THC for the treatment of chronic pain.
Nanbis is a side of cheek spray currently in the second stage of a cancer pain trial. In October 2018, Medlab announced successful completion of stage 1 of the trial at Royal North Shore Hospital in Sydney, which is the safety and tolerability phase.
This data has been compared to published data of an approved medicinal cannabis medication listed on the ARTG, showing similar plasma levels of THC and CBD with half the dose, and a faster absorption rate. This indicates that Nanabis is a more effective delivery method of active ingredients than the approved comparison.
Stage 2 will focus on further safety, tolerance and dose escalation.
MedLab also released a number of case studies to demonstrate the effectiveness of Nanabis. These indicated significant improvements in quality of life from reduction in pain and better sleep, and reduction of other medications.
